News Update: Shares of ImmunoGen, Inc. Up After 40% Plunge from Friday
Shares of ImmunoGen, Inc. (NASDAQ:IMGN) were up 10% earlier Monday to $5.66, reports Market Watch. Shares of the company dove 40% last Friday after the accelerated approval of the Roche Holding Ltd.-developed breast cancer treatment, T-DM1, was denied by the US Food and Drug Administration. Roche will now have to wait until mid-2012 to re-apply for approval. SmarTrend currently has ImmunoGen in a Downtrend and is monitoring these developments to alert subscribers to any change of trend. Shares of the pharmaceuticals company continue to trade up 11.05% Monday afternoon at $5.73.
Categories: Breast Cancer Treatment Tags: after, Friday, From, ImmunoGen, Inc., News, plunge, Shares, Update
Interview With the CEO of Radient Pharmaceuticals Provides Perspective as Company Shares See Increased Volume and …
Interview With the CEO of Radient Pharmaceuticals Provides Perspective as Company Shares See Increased Volume and …
LOS ANGELES, CA–(Marketwire – 12/27/10) – During the past few sessions, shares of Radient Pharmaceuticals (AMEX: RPC – News ) have seen increased volume and appreciation in anticipation of several key developments slated to occur in the short term. In an exclusive interview with BioMedReports, the leading news portal dedicated to delivering market intelligence to the biotech and medical …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Information Tags: company., Increased, Interview, Perspective, Pharmaceuticals, Provides, Radient, Shares, Volume
Susan Shares Her Breast Cancer Story – Needle Biopsy
Susan discusses what her needle biopsy was like. Go to www.EmpowHer.com to get more breast cancer treatment information. Share your cancer story & send this free video to a friend in need.
Roche shares down 4 percent on FDA Avastin setback
Roche shares down 4 percent on FDA Avastin setback
(AP:GENEVA) Roche Holding AG shares were trading Wednesday at their lowest level in more than a year after a panel of cancer experts recommended that the U.S. government should remove its endorsement of Avastin for breast cancer.
Read more on INO News
Shares jump for potential targets of Sanofi deal
Shares jump for potential targets of Sanofi deal
FILE – In this May 12, 2009 file photo, Sanofi CEO Chris Viehbacher, delivers his speech during the launch of Sanofi Pasteur’s new plant. Rumors French pharmaceutical giant Sanofi-Aventis SA is chasing a big U.S. acquisition Friday, July 2, 2010, have driven up shares of companies investors think might be a target.(AP Photo/Laurent Cipriani, file)
Read more on Ventura County Star